Vitamin D Inadequacy in Rural Populations, Evaluation of Correction by Food Supplementation

Sponsor
University of Wisconsin, Madison (Other)
Overall Status
Completed
CT.gov ID
NCT00690417
Collaborator
(none)
108
1
2
48
2.3

Study Details

Study Description

Brief Summary

The purpose of the research is to describe vitamin D levels and bone status in a rural Wisconsin population. It is probable that individuals of varying age and ethnicity require different amounts of D to achieve optimal status. These likely scenarios will be explored in various populations. We hypothesize that the increase in serum 25(OH)D resulting from daily D3 ingestion is less pronounced with advancing age and different in Native than Caucasian Americans. In addition, the women in the middle age group, between the ages of 55 and 65, will have ultrasound tests completed to assess the impact of the Vitamin D supplementation on cardiovascular health.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Cholecalciferol (vitamin D3)
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
108 participants
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Vitamin D Inadequacy: Documentation in Rural Populations and Evaluation of Correction by Food Supplementation (Phase III; Manitowoc Prevalence Study)
Study Start Date :
Aug 1, 2007
Actual Primary Completion Date :
Aug 1, 2011
Actual Study Completion Date :
Aug 1, 2011

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: 1

Dietary Supplement: Cholecalciferol (vitamin D3)
low calorie (~60 calories) cookie-like disc containing 2,500 IU of vitamin D3, taken by mouth daily for 4 months

Active Comparator: 2. 2500 IU vitamin D in a food preparation

Daily ingestion of 2500 IU vitamin D in a food preparation.

Dietary Supplement: Cholecalciferol (vitamin D3)
low calorie (~60 calories) cookie-like disc containing 2,500 IU of vitamin D3, taken by mouth daily for 4 months

Outcome Measures

Primary Outcome Measures

  1. the primary outcome is the proportion of postmenopausal women with D inadequacy defined by current consensus as a serum 25(OH)D < 30 ng/ml. [2.5 years]

Secondary Outcome Measures

  1. Prevalence of Vitamin D insufficiency in rural populations and ethnic differences in response to vitamin D supplementation [2.5 year]

  2. The relationship between vitamin D supplementation and cardiovascular disease. [2.5 Years]

Eligibility Criteria

Criteria

Ages Eligible for Study:
55 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion criteria:
  • Healthy, community-dwelling ambulatory women.

  • Able and willing to sign informed consent.

  • Ages: 20-30, 55-65 or >75

  • Baseline serum 25OHD concentration > 10 ng/ml and < 60 ng/ml

  • Not pregnant

  • Willing to avoid use of cod-liver oil and non-study vitamin D supplementation; standard multiple vitamins containing ≤ 400 IU used no more than once daily will be allowed.

  • Willing to utilize sunscreen of SPF-15 or higher when sun exposure for more than 15 minutes is expected.

Exclusion criteria:
  • Current hypercalcemia (serum calcium > 10.5 mg/dl) or untreated primary hyperparathyroidism.

  • History of nephrolithiasis

  • Baseline 24-hour urine calcium > 250 mg

  • Known risk factors for hypercalcemia, e.g., malignancy, tuberculosis, sarcoidosis, Paget's disease.

  • History of any form of cancer within the past five years with the exception of adequately treated squamous cell or basal cell skin carcinoma.

  • Renal failure; defined as a calculated creatinine clearance (using the Cockroft-Gault approach) of ≤ 25 ml/minute.

  • Severe end-organ disease, e.g., cardiovascular, hepatic, hematologic, pulmonary, etc., which might limit the ability to complete this study.

  • Treatment with any drug known to interfere with vitamin D metabolism, e.g., phenytoin, phenobarbital.

  • Known malabsorption syndromes, e.g., celiac disease, active inflammatory bowel disease, etc.

  • Known allergy to chocolate.

  • Use of medications known to alter bone turnover including bisphosphonates, estrogen, selective estrogen receptor modulators, parathyroid hormone, testosterone or calcitonin.

  • Treatment with high dose vitamin D (≥ 50,000 IU weekly) or any active metabolites of vitamin D, e.g., calcitriol, within six months of screening.

  • Use of tanning beds or salons or unwillingness to utilize sunscreen during periods of sun exposure of 15 minutes or longer.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Wisconsin Osteoporosis Clinical and Research Program Madison Wisconsin United States 53705

Sponsors and Collaborators

  • University of Wisconsin, Madison

Investigators

  • Principal Investigator: Neil Binkley, MD, University of Wisconsin - Institute on Aging

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Wisconsin, Madison
ClinicalTrials.gov Identifier:
NCT00690417
Other Study ID Numbers:
  • 2007-0211
First Posted:
Jun 4, 2008
Last Update Posted:
Nov 24, 2011
Last Verified:
Nov 1, 2011
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 24, 2011